March 20, 2026

Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China

Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China
  • First patient dosed in Huadong’s Phase I study with HDP-101 in China
  • Trial will evaluate safety, tolerability, pharmacokinetics and efficacy of HDP-101 in Chinese population with plasma cell disorders including multiple myeloma

Ladenburg, Germany, 18 March 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its partner Huadong Medicine Co., Ltd., Hangzhou, China, (SZ 000963; Huadong) has reached a development milestone under the terms of the license agreement from February 2022. With the dosing of the first patient in a clinical study with HDP-101 (INN: pamlectabart tismanitin) in China, a planned milestone payment to Heidelberg Pharma became due and is being processed. Financial details were not disclosed.

The clinical Phase I trial will evaluate the safety, tolerability, pharmacokinetics and efficacy of Heidelberg Pharma’s lead ATAC candidate pamlectabart tismanitin in Chinese population with plasma cell disorders including multiple myeloma. This bridging study is conducted in addition to the existing clinical program with this ATAC to ensure that safety and efficacy of the ATAC is comparable across diverse populations. The study has initiated dosing at 140 µg/kg, a dose level previously shown to be safe and well tolerated in the Caucasian ethnicity.

Dr. Donghzou Jeffery Liu, Chief Executive Officer of Heidelberg Pharma AG, commented: “The start of clinical development in China is an important milestone for us and Huadong, enabling us to test this product candidate not only in Europe and the US but also in Asia. With our unique payload Amanitin we have a clear differentiation in the ADC space. We are confident that pamlectabart tismanitin will demonstrate consistent safety and tolerability in the Chinese population and firmly believe in its therapeutic potential for various patient groups.”

Our latest News

discover more
2026 BioTech Breakthrough Honors VectorBuilder With “Overall CGT Solution Provider of the Year”

2026 BioTech Breakthrough Honors VectorBuilder With “Overall CGT Solution Provider of the Year”

Annual awards program recognizes innovation in life sciences and biotechnology worldwide CHICAGO, November 5, 2026 – VectorBuilder, a global leader in gene delivery technologies, today announced it has been named “Overall CGT Solution Provider of the Year” in the sixth annual BioTech Breakthrough Awards, recognizing innovation across the global life sciences and biotechnology industries. VectorBuilder integrates vector […]

Breast Milk for the Youngest Babies: New Milk Bank at Heidelberg University Hospital

Breast Milk for the Youngest Babies: New Milk Bank at Heidelberg University Hospital

The Heidelberg University Hospital (UKHD) recently launched “HeidelMilk,” a breast milk donation bank. It provides premature infants with donated breast milk when their own mothers’ milk supply is insufficient. To mark World Prematurity Day on November 15, the UKHD is introducing this new service. Full Text in German below. Muttermilch für die Kleinsten: Neue Milchbank […]

When Brake Cells Become Killer Cells: Double Honor for DKFZ Researcher Julius Michel

When Brake Cells Become Killer Cells: Double Honor for DKFZ Researcher Julius Michel

Julius Michel, a postdoctoral researcher at the German Cancer Research Center (DKFZ), has received two awards: the Craig Tendler Award for Myeloma Research from the American Society of Hematology – awarded for the first time and accompanied by a $10,000 prize – as well as another award from the society. He has discovered that a […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp